EUVIMEDAtklāt EUVIMED
KohortenstudieOpen access · CC BY 4.0

Systemic inflammation and prognosis in patients with RAS / BRAF wild‐type metastatic colorectal cancer receiving anti‐ EGFR therapy: A real‐world cohort study

Jordan W Appleyard iD, Faye Elliott, Nancy L Sapanara, Liping Zhang, Uday Kurkure, Jenny F Seligmann, Nicholas P West iD, Kandavel Shanmugam, Philip Quirke, Christopher J M Williams iD, N6 Collaboration

Colorectal Disease · 2026

DOI: 10.1111/codi.70639 ↗

At a glance

Kohortenstudie in Colorectal Disease, 2026. Written by Jordan W Appleyard and 10 co-authors. Institution: Division of Oncology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK. Major MEDLINE topics: Colorectal Neoplasms, Inflammation. 39 references. The full text is freely available (open access, CC BY 4.0). Funded by: Yorkshire Cancer Research, National Institute for Health and Care Research, Leeds Biomedical Research Centre, Cancer Research UK.

AbstraktsSubjectsBibliogrāfiskie datiCiteRelated studies

Abstract (original language)

Aim

Colorectal cancer outcomes are heterogeneous, so greater prognostic discrimination is needed. In this retrospective real‐world analysis, we assessed the prognostic effect of markers of systemic inflammation in a cohort of patients with RAS/BRAF wild‐type metastatic colorectal cancer (mCRC) who received anti‐EGFR therapy during routine care. We further examined the association between these markers and the known predictive biomarkers of anti‐EGFR efficacy, amphiregulin (AREG) and epiregulin (EREG).

Method

The prognostic effects of the neutrophil‐to‐lymphocyte ratio (NLR), platelet‐to‐lymphocyte ratio (PLR) and systemic immune‐inflammation index (SII) were tested. The cohort was randomly partitioned into training and validation sets (1:1). Cutoff values were defined in the training set, with analyses repeated in the validation set. The primary endpoint was overall survival (OS). Secondary endpoints were progression‐free survival (PFS), objective response rate and disease control rate.

Results

374 patients with RAS and BRAF wild‐type mCRC who received treatment with cetuximab or panitumumab across eight UK centres were included. NLR (≤ 4 vs. > 4) and PLR (≤ 200 vs. > 200) were independently prognostic for both OS and PFS. SII (≤ 900 vs. > 900) gave the strongest prognostic signal (OS: adjusted HR 1.63 [1.26–2.11], p = 0.0002 and PFS: adjusted HR 1.62 [1.26–2.08], p = 0.0001). There were no associations between NLR or PLR with AREG or EREG, suggesting anti‐EGFR benefit in AREG/EREG‐high tumours is not related to systemic inflammation.

Conclusion

Routinely assessed markers of systemic inflammation are independently prognostic in patients with mCRC receiving anti‐EGFR therapy and may serve as useful adjuncts in informing discussions with patients about prognosis.

Subjects

MeSH terms (MEDLINE)

Colorectal NeoplasmsInflammationHumansFemaleErbB ReceptorsPrognosisRetrospective StudiesCetuximabAmphiregulinPanitumumabMaleAgedEpiregulinMiddle AgedProto-Oncogene Proteins B-rafNeutrophilsBiomarkers, TumorLymphocytesProgression-Free SurvivalCohort Studies

Author keywords

amphiregulinanti‐EGFRcetuximabepiregulinmetastatic colorectal cancerneutrophil‐to‐lymphocyte ratiopanitumumabplatelet‐to‐lymphocyte ratiosystemic immune‐inflammation index

Substances

ErbB ReceptorsCetuximabAmphiregulinPanitumumabEpiregulinProto-Oncogene Proteins B-rafBRAF protein, humanEREG protein, humanBiomarkers, TumorAREG protein, human

Authors and institutions

  • Division of Oncology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK.
  • Division of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK.
  • Clinical Development & Medical Affairs, Roche Diagnostics Solutions, Tucson, Arizona, USA.
  • Computational Science and Informatics, Roche Diagnostics Solutions, Santa Clara, California, USA.
  • Division of Pathology and Data Analytics, Leeds Institute of Medical Research, University of Leeds, Leeds, UK.

ORCID profiles: Jordan W Appleyard, Nicholas P West, Christopher J M Williams

Funding

  • Yorkshire Cancer Research
  • National Institute for Health and Care Research, Leeds Biomedical Research Centre
  • Cancer Research UK
  • UK Research and Innovation (UKRI)
  • National Institute for Health and Care Research

Cite

APA

Appleyard, J. W., Elliott, F., Sapanara, N. L., Zhang, L., Kurkure, U., Seligmann, J. F., West, N. P., Shanmugam, K., Quirke, P., Williams, C. J. M., & N6 Collaboration (2026). Systemic inflammation and prognosis in patients with RAS / BRAF wild‐type metastatic colorectal cancer receiving anti‐ EGFR therapy: A real‐world cohort study. Colorectal Disease. https://doi.org/10.1111/codi.70639

Vancouver

Appleyard JW, Elliott F, Sapanara NL, Zhang L, Kurkure U, Seligmann JF, et al. Systemic inflammation and prognosis in patients with RAS / BRAF wild‐type metastatic colorectal cancer receiving anti‐ EGFR therapy: A real‐world cohort study. Colorectal Disease. 2026. doi:10.1111/codi.70639

BibTeX
@article{Appleyard2026,
  author = {Appleyard, Jordan W and Elliott, Faye and Sapanara, Nancy L and Zhang, Liping and Kurkure, Uday and Seligmann, Jenny F and West, Nicholas P and Shanmugam, Kandavel and Quirke, Philip and Williams, Christopher J M and N6 Collaboration, N6 Collaboration},
  title = {Systemic inflammation and prognosis in patients with RAS / BRAF wild‐type metastatic colorectal cancer receiving anti‐ EGFR therapy: A real‐world cohort study},
  journal = {Colorectal Disease},
  year = {2026},
  doi = {10.1111/codi.70639}
}
Start for free →